118 related articles for article (PubMed ID: 10070309)
1. Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumours.
Zhou Y; Gobl A; Wang S; Jacobsen MB; Janson ET; Haines GK; Radosevich JA; Oberg K
Eur J Cancer; 1998 Dec; 34(13):2046-52. PubMed ID: 10070309
[TBL] [Abstract][Full Text] [Related]
2. Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumors.
Zhou Y; Wang S; Gobl A; Oberg K
Oncology; 2001; 60(4):330-8. PubMed ID: 11408801
[TBL] [Abstract][Full Text] [Related]
3. The interferon-alpha regulation of interferon regulatory factor 1 (IRF-1) and IRF-2 has therapeutic implications in carcinoid tumors.
Zhou Y; Wang S; Gobl A; Oberg K
Ann Oncol; 2000 Jun; 11(6):707-14. PubMed ID: 10942060
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG
Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of double-stranded-RNA-dependent protein kinase (p68) with a novel monoclonal antibody TJ4C4. A case report of an AIDS-associated Kaposi's sarcoma treated with alpha-interferon.
Haines GK; Ghadge GD; Combs SG; Leslie W; Thimmappaya B; Radosevich JA
Tumour Biol; 1992; 13(5-6):324-9. PubMed ID: 1283928
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
Bajetta E; Zilembo N; Di Bartolomeo M; Di Leo A; Pilotti S; Bochicchio AM; Castellani R; Buzzoni R; Celio L; Dogliotti L
Cancer; 1993 Nov; 72(10):3099-105. PubMed ID: 7693327
[TBL] [Abstract][Full Text] [Related]
7. Expression of the protein kinase p-68 recognized by the monoclonal antibody TJ4C4 in human lung neoplasms.
Haines GK; Ghadge G; Thimmappaya B; Radosevich JA
Virchows Arch B Cell Pathol Incl Mol Pathol; 1992; 62(3):151-8. PubMed ID: 1357815
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CDK2, CDK4 and cyclin E and increased expression of p27Kip1 during treatment with interferon-alpha in carcinoid tumor cells.
Zhou Y; Wang S; Gobl A; Oberg K
J Biol Regul Homeost Agents; 1999; 13(4):207-15. PubMed ID: 10703944
[TBL] [Abstract][Full Text] [Related]
9. Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours.
Causevic M; Hislop RG; Kernohan NM; Carey FA; Kay RA; Steele RJ; Fuller-Pace FV
Oncogene; 2001 Nov; 20(53):7734-43. PubMed ID: 11753651
[TBL] [Abstract][Full Text] [Related]
10. The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors.
Oberg K; Eriksson B; Janson ET
Ann N Y Acad Sci; 1994 Sep; 733():471-8. PubMed ID: 7978897
[No Abstract] [Full Text] [Related]
11. IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro.
Vitale G; de Herder WW; van Koetsveld PM; Waaijers M; Schoordijk W; Croze E; Colao A; Lamberts SW; Hofland LJ
Cancer Res; 2006 Jan; 66(1):554-62. PubMed ID: 16397272
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases].
Votte A; Iglicki F; Sévenet F; Tabah I; Dupas JL
Presse Med; 1996 Jan; 25(2):63-7. PubMed ID: 8745720
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.
Saltz L; Kemeny N; Schwartz G; Kelsen D
Cancer; 1994 Aug; 74(3):958-61. PubMed ID: 8039124
[TBL] [Abstract][Full Text] [Related]
14. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours.
Schöber C; Schmoll E; Schmoll HJ; Poliwoda H; Schuppert F; Stahl M; Bokemeyer C; Wilke H; Weiss J
Eur J Cancer; 1992; 28A(10):1664-6. PubMed ID: 1382494
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
16. Induction of MxA mRNA in patients with neuroendocrine tumors after interferon treatment. Lack of correlation with antitumor response.
Imam H; Janson ET; Gobl A; Alm G; Oberg K
Anticancer Res; 1995; 15(5B):2191-5. PubMed ID: 8572623
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha induces bcl-2 proto-oncogene in patients with neuroendocrine gut tumor responding to its antitumor action.
Imam H; Gobl A; Eriksson B; Oberg K
Anticancer Res; 1997; 17(6D):4659-65. PubMed ID: 9494585
[TBL] [Abstract][Full Text] [Related]
18. The action of interferon alpha on human carcinoid tumours.
Oberg K
Semin Cancer Biol; 1992 Feb; 3(1):35-41. PubMed ID: 1353693
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.
Ramage JK; Davies AH; Ardill J; Bax N; Caplin M; Grossman A; Hawkins R; McNicol AM; Reed N; Sutton R; Thakker R; Aylwin S; Breen D; Britton K; Buchanan K; Corrie P; Gillams A; Lewington V; McCance D; Meeran K; Watkinson A;
Gut; 2005 Jun; 54 Suppl 4(Suppl 4):iv1-16. PubMed ID: 15888809
[No Abstract] [Full Text] [Related]
20. Novel therapy for the treatment of human carcinoid.
Evers BM; Hurlbut SC; Tyring SK; Townsend CM; Uchida T; Thompson JC
Ann Surg; 1991 May; 213(5):411-6. PubMed ID: 1708983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
